Skip to main content
. Author manuscript; available in PMC: 2014 May 20.
Published in final edited form as: Clin Cancer Res. 2011 Jul 7;17(16):5367–5378. doi: 10.1158/1078-0432.CCR-10-3176

Figure 3. Modulation of src kinase activity with oxaliplatin and dasatinib.

Figure 3

(A) Western blot analysis for phospho-src, src, phospho-AKT, and AKT is shown over time. RMUG-S-ip2 and SKOV3-TR were treated with IC50 dose of oxaliplatin (RMUG-S-ip2 15.6 μg/mL, and SKOV3-TR 5.2 μg/mL). (B, C) Western blot analysis for dose-kinetic study is shown for RMUG-S-ip2 treated with dasatinib alone (B) or dasatinib with oxaliplatin (C). The experiment time was stopped at 30 mins. IC50 dose of oxaliplatin (15.6 μg/mL) was used.